Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrgastro.2012.96 http://scihub22266oqcxt.onion/10.1038/nrgastro.2012.96 22614754!ä!22614754 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\22614754.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nat+Rev+Gastroenterol+Hepatol 2012 ; 9 (7): 382-91 Nephropedia Template TP {{tp|p=22614754|t=2012. Recent advances in our understanding of hepatorenal syndrome |pdf=|usr=}}{{22614754}} gab.com Text Recent advances in our understanding of hepatorenal syndrome JO: Nat Rev Gastroenterol Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=22614754 #FOAvip Hepatorenal syndrome (HRS) is a serious complication of advanced cirrhosis with ascites. HRS develops as a result of abnormal haemodynamics, leading to splanchnic and systemic vasodilatation, but renal vasoconstriction. Increased bacterial translocation, various cytokines and mesenteric angiogenesis also contribute to splanchnic vasodilatation, and altered renal autoregulation is involved in the renal vasoconstriction. Type 1 HRS is usually initiated by a precipitating event associated with an exaggerated systemic inflammatory response that perturbs haemodynamics, resulting in multiorgan failure. An inadequate cardiac output with systolic incompetence increases the risk of renal failure. Vasoconstrictors are the main treatment in patients with type 1 HRS; terlipressin is the superior agent. Norepinephrine is similar to terlipressin in efficacy and can be used as an alternative. Transjugular intrahepatic portosystemic stent shunt might be applicable in a small number of patients with type 1 HRS and in most patients with type 2 HRS. Liver transplantation is the definitive treatment for HRS, and should be performed after reversal of HRS. In nonresponders to vasoconstrictor therapy, much controversy still exists as to whether to do simultaneous or sequential liver and kidney transplant. In general, patients who have had >8-12 weeks of pretransplant dialysis should be considered for combined liver-kidney transplantation. Twit Text FOAVip Recent advances in our understanding of hepatorenal syndrome ????Nat Rev Gastroenterol Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=22614754 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22614754 #FOAvip English Wikipedia <ref>{{Cite pmid|22614754}}</ref> Recent advances in our understanding of hepatorenal syndrome #MMPMID22614754 Wong F Nat Rev Gastroenterol Hepatol 2012[May]; 9 (7): 382-91 PMID22614754show ga Hepatorenal syndrome (HRS) is a serious complication of advanced cirrhosis with ascites. HRS develops as a result of abnormal haemodynamics, leading to splanchnic and systemic vasodilatation, but renal vasoconstriction. Increased bacterial translocation, various cytokines and mesenteric angiogenesis also contribute to splanchnic vasodilatation, and altered renal autoregulation is involved in the renal vasoconstriction. Type 1 HRS is usually initiated by a precipitating event associated with an exaggerated systemic inflammatory response that perturbs haemodynamics, resulting in multiorgan failure. An inadequate cardiac output with systolic incompetence increases the risk of renal failure. Vasoconstrictors are the main treatment in patients with type 1 HRS; terlipressin is the superior agent. Norepinephrine is similar to terlipressin in efficacy and can be used as an alternative. Transjugular intrahepatic portosystemic stent shunt might be applicable in a small number of patients with type 1 HRS and in most patients with type 2 HRS. Liver transplantation is the definitive treatment for HRS, and should be performed after reversal of HRS. In nonresponders to vasoconstrictor therapy, much controversy still exists as to whether to do simultaneous or sequential liver and kidney transplant. In general, patients who have had >8-12 weeks of pretransplant dialysis should be considered for combined liver-kidney transplantation. |*Liver Transplantation[MESH] |Comorbidity[MESH] |Hemodynamics/*physiology[MESH] |Hepatorenal Syndrome/diagnosis/*physiopathology/*therapy[MESH] |Humans[MESH] |Liver Cirrhosis/epidemiology[MESH] |Lypressin/analogs & derivatives/therapeutic use[MESH] |Norepinephrine/therapeutic use[MESH] |Terlipressin[MESH] |Treatment Outcome[MESH]Recent advances in our understanding of hepatorenal syndrome (epmc).pdf DeepDyve Pubget Overpricing